Menu
Not yet recruiting NCT06942728

Personalized Medicine in the Elderly With Vision Impairment and Mild Cognitive Impairment

No phase Interventional Mild Cognitive Impairment

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: nLIFE EyeFitness.
Who it may be relevant to
Registry conditions: Mild Cognitive Impairment. Basic parameters: 60 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Personalized Medicine in the Elderly With Vision Impairment and Mild Cognitive Impairment: Effects of Sensorineural Telerahabilitation

Overview

Globally, approximately 55 million people suffer from dementia, and 60-70% of cases are due to Alzheimer's disease (AD). Increasing scientific evidence highlights that the pathological changes underlying AD and other forms of dementia begin long before the onset of symptoms. Mild cognitive impairment (MCI) is a clinical condition that in people over 65 shows a prevalence ranging from 3% to 22%. The characteristics of MCI are the presence of a subjective memory disorder and a reduced ability to learn new information with normal general cognitive functioning, normal ability to perform daily activities and the absence of other conditions, such as depression, that could justify the memory disorder. Currently, the diagnosis of MCI is based exclusively on clinical evaluation, including neuropsychological tests. Currently, there are no therapies available to prevent and/or treat dementia and the options for intervention are represented by treatments such as physical exercise and cognitive treatment. These practices refer to the concept of cognitive reserve. Computerized cognitive training (CCT) is characterized by being a personalized intervention, allows multi-domain training and increases the cognitive processes of patients with MCI. The National Low Vision Center has been using a software called nLIFE EyeFitness for several years, certified as a Class I Medical device. It allows you to carry out individualized rehabilitation exercises at home, using your own PC or tablet, with monitoring by the Center's operators. The exercises currently present stimulate attention, short-term visual memory, reaction time, executive function, working memory and, therefore, also appear suitable for stimulating subjects with MCI.

Interventions

  • Device nLIFE EyeFitness
    A software called nLIFE EyeFitness, certified as a Class I Medical device, allows to carry out individualized rehabilitation exercises at home, using own PC or tablet, with monitoring by the Center's operators.

Primary outcome measures

  • The effects of neurosensory telerehabilitation in elderly subjects with MCI [Time frame: 8 months]
Secondary outcome measures (1)
  • Evaluation the effects of neurosensory telerehabilitation on visual tests score [Time frame: 8 months]

Eligibility criteria

Inclusion criteria

  • Patients aged ≥ 60 years with a diagnosis of aMCI
  • Signing of informed consent

Exclusion criteria

  • Age <60 years
  • History of dementia
  • Diabetes mellitus
  • Uncontrolled hypertension
  • Diagnosis of major depression
  • Glaucoma
  • Age-related macular degeneration
  • Media opacity and vitreoretinal pathologies that may preclude a correct evaluation
  • • Failure to obtain informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

Italy · 1 center
  • Fondazione Policlinico Universitario A. Gemelli IRCCS, Polo Nazionale Ipovisione — Rome

Identifiers

NCT: NCT06942728 · 5032

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗